Participated · Series A · Jun 2026

Apothékary is a consumer wellness brand selling plant-based adaptogen supplements marketed as alternatives to alcohol and pharmaceuticals. The company is led by founder Shizu Okusa. Apothékary has been expanding into retail, launching in Ulta Beauty, Whole Foods, and The Vitamin Shoppe. It reported a target of roughly $35M in sales in 2025 and is aiming for $40M in sales in 2026. Financially, the company has raised about $32M to date across equity and debt and just completed a $16M Series A composed of equity and debt to support further retail growth.

Participated · Equity · Sep 2023

Chitose Bio Evolution is a Singapore-headquartered biotech firm. It announced a fresh inflow of capital totaling 1 billion yen (about $6.2 million) from Japan’s Sumitomo Mitsui Banking Corporation (SMBC). The article characterizes the funds as an investment from SMBC. The report does not provide details on the company’s core products, pipeline, or future plans. No operating metrics, past funding rounds, or founding year were disclosed in the article. CHITOSE BIO EVOLUTION is the CHITOSE Group headquarters leading development of large-scale photosynthetic microalgae production technologies and the MATSURI project. The company produces microalgae for fuels, foods, chemical products, cosmetics, and feedstuffs while developing multifaceted applications to replace petroleum-derived inputs. CHITOSE has scaled facilities from a 0.1-hectare plant in 2018 to the 5-hectare CHITOSE Carbon Capture Central (C4) inaugurated in April 2023 and plans to expand to 2,000 hectares by 2030 and 10 million hectares by 2050. Recent fundraising will be used to expand production capacity and accelerate R&D of product applications under MATSURI. CHITOSE’s initial 100-hectare facility development and application R&D have been selected as a commissioned project by the Green Innovation Fund/NEDO. CHITOSE BIO EVOLUTION was established in October 2011 and is headquartered in Singapore; the CHITOSE Group also includes CHITOSE Laboratory Corp. in Kanagawa, Japan. In the current fiscal year the group achieved a $20M fundraising target during the first half and intends to continue investor discussions to meet further procurement plans.

Participated · Equity · Oct 2021

FemTec Health is launching a unified platform that uses a patent-pending BiomeAI™ engine to translate consumer, genetic, microbiome, and biometric data into personalized healthcare and beauty offerings. The company says its platform can be applied across specialty care, wellness and prevention, reproductive care, sexual wellness, mental health, and chronic care. FemTec emerged from stealth with about 10 million members, two clinical trials in progress, and a team of over 150. The company has pursued growth via acquisitions, having acquired Birchbox, Mira Beauty, and Liquid Grids, and plans to relaunch Birchbox using the BiomeAI platform to deliver curated personalized products. FemTec was developed beginning in May 2020 and is led by Houston health-tech entrepreneur Dr. Kimon Angelides, who serves as chairman and interim CEO, alongside chief scientific officer Dr. Kimberly Capone and COO Dr. Laura Clapper. The company intends to announce additional strategic partnerships with health and wellness companies.

Participated · Equity · May 2019

airfree operates an inflight e/m-commerce platform that creates a white-label duty-free marketplace for airlines, offering a digital catalog of more than 10,000 references and a click-&-collect model. The platform downloads data before takeoff to minimize onboard connectivity needs and, in tests, used on average 50 times less satellite bandwidth than a traditional e-commerce site. airfree positions its solution to boost airport duty-free retailer sales and increase airline revenues by controlling satellite connectivity costs and improving passenger experience. The company completed a technical proof of concept in partnership with Singapore Airlines' Krislab program and conducted tests with inflight connectivity suppliers. The team was founded in 2016, has about ten people including developers, and aims for a commercial launch at the end of 2019. The fundraising announced will support a pilot in real conditions and accelerate that commercial rollout.